Neurofibromatosis Type 1 Clinical Trial
Official title:
Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children
The present project will therefore focus upon those processes related to visual attention and perceptual abilities and on their potential to explain reading behavior and reading problems in NF1. The main objective of this study is to clarify the specificity and heterogeneity of reading profiles and the causes of its disturbance in NF1. In particular, this project allow the investigators to study more precisely the relations between perceptual, oculomotor and visuo-attentional skills in NF1 children and reading abilities. In addition, a new oculomotor/perceptual reading aid for NF1 children will be evaluated. The investigators believe that the early intervention for perceptual, visuo-attentional or oculomotor problems may promote academic skill development.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | May 2019 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 9 Years |
Eligibility |
Inclusion Criteria: - Child with a NF1 following the clinically-based criteria agreed at the international Consensus Conference - Age between 7 and 9 years old child in 1st - 3rd grades with 5 children/grade - Informed children and written consent obtained from one of the parents or other lawful representative - Child who is covered by the social security scheme Exclusion Criteria: - left-handed children - associated neurological disorder such as brain tumors or epilepsy - mental retardation (IQ <70 or Wechsler Intelligence Scale for Children (WISC) scores SIM et IC < 7) - children with Autism Spectrum Disorder - diagnosis of attention deficit hyperactivity disorder (ADHD) (DSM-IV), with presence of hyperactive-impulsive or inattentive symptom - pharmaceutical treatment (e.g., anti-depressants, anxiolytics) |
Country | Name | City | State |
---|---|---|---|
France | University Hospital Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Toulouse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of the score obtained for Oculomotor Processes | The visual process : Oculomotor Processes : Vertical,Horizontal Time with the Ratio with the Developmental Eye Movement Test (DEM test) : a standard of evaluation oculomotor in children with reading difficulties | 1 day | |
Primary | Evaluation of the composite score obtained for Visuo-perceptual process | The visual process : Visuo-perceptual process : it's a composite score : Composite score of perceptual treatment with pure visual perception score and visuo-motor integration with a Developmental Test of Visual Perception, 3rd (DTVP3) test is Visual perception development test | 1 day | |
Primary | Evaluation of the score obtained : Visual-attentional process | Visual-attentional process : reaction time (milli Sec) with the percentage of correct answers to the computerized Stroop to show that attention is a selective process and that it is very difficult to read and name colors at the same time | 1 day | |
Secondary | Alouette Reading Test | To evaluate language skills like phonological awareness with lexical stock Alouette Reading Test's aim is for the accuracy index and CTL speed index :The Alouette test is a reading test that evaluates the level of lexical decoding (automaticity). It consists of reading a standard text aloud and count the number of words read and errors in a given time | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03190915 -
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT03326388 -
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01218139 -
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
|
N/A | |
Recruiting |
NCT05149469 -
Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
|
||
Not yet recruiting |
NCT02505412 -
Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
|
N/A | |
Terminated |
NCT02256124 -
Effect of Lamotrigine on Cognition in NF1
|
Phase 2/Phase 3 | |
Completed |
NCT01707836 -
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
|
N/A | |
Active, not recruiting |
NCT01218152 -
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
|
N/A | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
Recruiting |
NCT05186870 -
Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
|
||
Active, not recruiting |
NCT03231306 -
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
|
Phase 2 | |
Withdrawn |
NCT03332030 -
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
|
||
Recruiting |
NCT02964884 -
Interventions for Reading Disabilities in NF1
|
Phase 2 | |
Recruiting |
NCT05388370 -
PASS of Paediatric Patients Initiating Selumetinib
|
||
Recruiting |
NCT02777775 -
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
|
||
Completed |
NCT02944032 -
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT01851135 -
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT01410006 -
Neurofibromatosis Type 1 Patient Registry
|
N/A |